“Incidence of adverse and safety events in individuals with Parkinson’s disease treated with catechol-o-methyltransferase inhibitor opicapone as an add-on to levodopa treatment: a systematic review and meta-analysis” (2025) Prospects in Pharmaceutical Sciences, 23(4), pp. 175–185. doi:10.56782/pps.563.